Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.
about
RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disordersDRiPs solidify: progress in understanding endogenous MHC class I antigen processingMass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen PresentationPathways of antigen processing.A critical analysis of codon optimization in human therapeutics.The mRNP remodeling mediated by UPF1 promotes rapid degradation of replication-dependent histone mRNA.Nuclear translation visualized by ribosome-bound nascent chain puromycylation.Proteome sampling by the HLA class I antigen processing pathwayTranslation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathwayeIF4AIII enhances translation of nuclear cap-binding complex-bound mRNAs by promoting disruption of secondary structures in 5'UTR.Kinetics of antigen expression and epitope presentation during virus infection.Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.Regulation of cytoplasmic mRNA decay.Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptidesRapid degradation of replication-dependent histone mRNAs largely occurs on mRNAs bound by nuclear cap-binding proteins 80 and 20Rescue of nonsense mutations by amlexanox in human cells.Amsterdamming DRiPs.Nuclear translation for immunosurveillance.Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In VivoGoing Pro to enhance T-cell immunogenicity: easy as π?Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.Re-examining class-I presentation and the DRiP hypothesisThe nature and extent of contributions by defective ribosome products to the HLA peptidome.Post-transcriptional regulatory networks in immunity.The impact of macroautophagy on CD8(+) T-cell-mediated antiviral immunity.Cap-binding complex (CBC).Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.Lymphocyte repertoire selection and intracellular self/non-self-discrimination: historical overview.TAPBPR: a new player in the MHC class I presentation pathway.MHC structure and function - antigen presentation. Part 2I've got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells.Regulation of protein synthesis and autophagy in activated dendritic cells: implications for antigen processing and presentation.Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes.Autoimmune T cell recognition of alternative-reading-frame-encoded peptides.Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway.Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames.Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I.Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve.
P2860
Q26823908-06533EBC-84C3-44DB-875D-2764F549D5F5Q27006750-58275220-6F05-48A6-872C-3D5A57A96E11Q30002365-97364C47-7B3C-40C0-B69E-54808C878EA5Q33631854-4BF3901D-4911-49BE-ABA7-2C600328B731Q34042157-698EBEC8-2447-4372-907B-B36A88ECA9B9Q34044351-1A05E957-700D-4CFC-BA03-070CEB4949C3Q34265585-66FF2227-6394-4FB5-8056-AC465B63E406Q34276972-B06AEAEC-54D6-42F2-B646-590FFDA00EE2Q34374454-63FBDA0E-F28C-45BB-929B-627D6B8F613EQ34442451-19728CFE-D2E3-49DD-81D0-A2F92E384492Q34574829-6D596F22-03AE-4108-BE03-8F540A8B8BC9Q35641132-7B2E12F6-5D5E-49DA-8ACA-3BF441DE470FQ35955726-30E6AF6E-8161-4FC4-B14F-7A5677350431Q36342549-547B3CA3-E7B9-4DFC-BD1C-AB2C8083FD51Q36559271-B1D767F1-52D7-4F2F-81F9-3E82BE86A300Q36581500-4988C9C7-4F99-48C9-A8F7-89B89B6C1294Q36724559-BC4561F7-D9C0-445A-92AE-C13BD964A873Q37276555-71C30340-06B4-4DA9-A459-BCE8657E5970Q37467831-33A9CBCB-09C8-4CE7-ACC3-239742208123Q37474545-52117FF1-BF2D-48DA-8224-18F4B2D13A94Q37644973-9D09643B-A34C-45F0-857C-78FA83772C9FQ37682377-31DA5287-FB13-4E35-999F-93341D2379A5Q37702916-97A39745-25C4-44A2-BA3B-559FB69ACBF0Q37725183-D0EAD7EA-AE98-415A-82FF-97ADA568152FQ38095507-48FACEA8-9E04-4C40-9E65-F1E9026E2C95Q38129080-021FEB61-FB1E-47E6-B3EF-1339E16B3546Q38172648-8EADF86F-A191-446E-AEAD-2C906E39F24DQ38245881-F864D8D1-ADDD-486A-92EC-D4EC03808AA5Q38266751-34C92591-C2DB-4BF2-A5CC-F476AD4B58B3Q38365574-747995FB-FB14-4B28-A41A-E7C60387201BQ38390459-98D3F54E-0376-40A2-A2BC-C599B05D296AQ38731152-ECA4D87D-EA52-4352-969A-68708127C4B2Q38869709-FE9465FB-ABB4-41C6-A03F-DEDCB04AAD70Q40203174-7EC599FD-93A6-4895-9D55-5D0442F573DFQ40253057-B6A17F98-5753-4200-B8A3-282AB077E23CQ40264818-7C36132A-E081-4C2D-B677-2B0AF7EA558CQ41298097-F9DB8AB6-AC9C-41CB-B3B0-1B3577D7CEE5Q41906355-DCD2BE80-825D-4293-A5CB-FD8C8A956DF4Q42174739-07D8DCE6-FCB4-492C-A39E-F148549B872EQ42227411-76BAE638-2204-4101-B587-BBDBAF6CB61D
P2860
Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Major source of antigenic pept ...... eer round of mRNA translation.
@ast
Major source of antigenic pept ...... eer round of mRNA translation.
@en
type
label
Major source of antigenic pept ...... eer round of mRNA translation.
@ast
Major source of antigenic pept ...... eer round of mRNA translation.
@en
prefLabel
Major source of antigenic pept ...... eer round of mRNA translation.
@ast
Major source of antigenic pept ...... eer round of mRNA translation.
@en
P2093
P2860
P356
P1476
Major source of antigenic pept ...... eer round of mRNA translation.
@en
P2093
Chrysoula Daskalogianni
Gabriela Imhoos
Lea Heslop
Robin Fåhraeus
Sebastien Apcher
P2860
P304
11572-11577
P356
10.1073/PNAS.1104104108
P407
P577
2011-06-27T00:00:00Z